Clinical Trials

NCT IdNCT04872023
TitleImmunomonitoring and Multiple Myeloma: Impact of Lenalidomide on Immune Checkpoint Expression
ConditionMultiple Myeloma
OrganizationRennes University Hospital
Sponsor/CollaboratorsRennes University Hospital
StatusNot yet recruiting
Older Adult
Location (with distance)
  • CHU Rennes, Rennes, France
DescriptionThe myeloma microenvironment is the target of many drugs in development, and it is unclear how they can be combined with reference treatments such as lenalidomide. This pilot study consists of an extensive phenotypic characterisation of the impact of lenalidomide combined with dexamethasone on the bone marrow microenvironment of a homogeneous cohort of non-pretreated MM patients. Blood sampling will be systematically performed in a matched fashion to monitor the general effect of lenalidomide on the immune system and to detect possible peripheral markers. This study will provide rational guidance for future combination therapies with lenalidomide.